Pharma Journalist 9057 posts 0 comments

Aptar Pharma has partnered with Aceso Therapeutics to support the development of ACT-101, an antisense oligonucleotide (ASO) candidate being developed as a potential treatment for…
Read More...

The 9th Annual RNA-Targeted Drug Discovery & Development Summit will unite the scientists, drug developers, and industry leaders advancing RNA-targeted small molecules from early…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients.…
Read More...

GSK has reported positive Phase II results for its mRNA seasonal influenza vaccine candidate, with the company planning to begin a Phase III efficacy trial in September 2026. The…
Read More...

Médunik Canada has entered into an exclusive promotional services agreement with Biocodex for Diacomit®, a treatment used for seizures associated with Dravet syndrome in Canada.…
Read More...

Superluminal Medicines has raised $60 million in an oversubscribed Series B financing to advance its drug development programs, including a lead treatment for rare genetic forms of…
Read More...

Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in adults with relapsing multiple sclerosis (RMS). The oral…
Read More...

Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical to support the research and development of a fully human VHH antibody for…
Read More...

Typewriter Therapeutics has emerged from stealth with $56 million in Series A financing to develop genetic medicines for cancer, autoimmune diseases, and severe genetic disorders.…
Read More...

The World ADC Awards 2026 shortlist has been announced, recognizing the organizations, teams, technologies, and individuals driving innovation and advancing the field of antibody-drug…
Read More...